Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    • News

  • Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    • News

  • Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    • News

  • European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    • News

  • Harris Technology’s refurbished boom signals FY26 profit inflection
    Harris Technology’s refurbished boom signals FY26 profit inflection
    • News

Grain storage pests no match for Bio-Gene after Flavocide trials reach six-month mark

  • In News
  • September 3, 2019
  • Alfred Chan
Grain storage pests no match for Bio-Gene after Flavocide trials reach six-month mark

Since the commencement of their program to fight grain storage pests, Agriculture technology company Bio-Gene Technology (ASX: BGT) continues to report strong trial results with current trials reaching the six-month mark and still effectively preventing pest growth. 

As the world population continues expanding and higher food storage levels are required, loss of grains and grain-based products caused by insects and pests will emerge as a growing problem. These losses range from 10% product loss in temperate regions to 50% in tropical areas. 

Conducting the grain storage research trials in partnership with the Department of Agriculture & Fisheries, Queensland Government (DAF), Bio-Gene’s product Flavocide is proving an effective insecticide against the offspring of adult Lesser grain borers, a major grain storage pest. 

“We are delighted that this most recent trial work, to demonstrate the long-term efficacy of Flavocide, has proven to be positive,” said Bio-Gene CEO, Richard Jagger. 

“An increase from 3 months to 6 months residual control is an excellent outcome. This will hopefully create significant potential for commercial opportunities. 

“These results clearly demonstrate the potential for incorporating Flavocide into grain protection pest management programs and further strengthens the commercial viability of our product.”

Bio-Gene will now extend the testing to a nine-month assessment, continuing to test the efficacy of Flavocide and in combination with other chemical variants and against a broader range of target pests.

Similar to the human trend of increasing resistance to broad spectrum antibiotics as a result of continued generational use, pests are becoming increasingly resistant to older ranges of insecticides. As this problem increases alongside human food consumption trajectories, the protection for stored grain will become a rising economic necessity where grain used for domestic human consumption must not contain live insects. 

  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024
  •  
  •  
  •  
  •  
  • agri
  • agriculture
  • ASX.BGT
  • BGT
  • bio-gene
  • bio-gene technology
  • clinical trial
  • flavocide
  • food storage
  • trial results
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.